

# Ezequiel Ridruejo

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3985835/publications.pdf>

Version: 2024-02-01

93  
papers

3,310  
citations

279487

23  
h-index

149479

56  
g-index

97  
all docs

97  
docs citations

97  
times ranked

5152  
citing authors

#	ARTICLE	IF	CITATIONS
1	Global prevalence and genotype distribution of hepatitis C virus infection in 2015: a modelling study. <i>The Lancet Gastroenterology and Hepatology</i> , 2017, 2, 161-176.	3.7	1,619
2	The present and future disease burden of hepatitis <scp>C</scp> virus (<scp>HCV</scp>) infections with today's treatment paradigm â€“ volume 2. <i>Journal of Viral Hepatitis</i> , 2015, 22, 26-45.	1.0	117
3	The Latin American Association for the Study of the Liver (ALEH) position statement on the redefinition of fatty liver disease. <i>The Lancet Gastroenterology and Hepatology</i> , 2021, 6, 65-72.	3.7	108
4	Historical epidemiology of hepatitis C virus (<scp>HCV</scp>) in select countries â€“ volume 2. <i>Journal of Viral Hepatitis</i> , 2015, 22, 6-25.	1.0	92
5	Imatinib-induced fatal acute liver failure. <i>World Journal of Gastroenterology</i> , 2007, 13, 6608.	1.4	79
6	The liver in times of COVID-19: What hepatologists should know. <i>Annals of Hepatology</i> , 2020, 19, 353-358.	0.6	72
7	Treatment with direct-acting antivirals for HCV decreases but does not eliminate the risk of hepatocellular carcinoma. <i>Liver International</i> , 2019, 39, 1033-1043.	1.9	65
8	Efficacy and safety of long term entecavir in chronic hepatitis B treatment naÃ“ve patients in clinical practice. <i>Annals of Hepatology</i> , 2014, 13, 327-336.	0.6	59
9	Liver injury after SARSâ€“CoVâ€“2 vaccination: Features of immune-â€“mediated hepatitis, role of corticosteroid therapy and outcome. <i>Hepatology</i> , 2022, 76, 1576-1586.	3.6	58
10	Outcome of COVIDâ€“19 in Patients With Autoimmune Hepatitis: An International Multicenter Study. <i>Hepatology</i> , 2021, 73, 2099-2109.	3.6	56
11	Disease Progression in Patients With Hepatitis C Virus Infection Treated With Direct-Acting Antiviral Agents. <i>Clinical Gastroenterology and Hepatology</i> , 2020, 18, 2554-2563.e3.	2.4	48
12	Strategies to manage hepatitis <scp>C</scp> virus (<scp>HCV</scp>) infection disease burden â€“ volume 2. <i>Journal of Viral Hepatitis</i> , 2015, 22, 46-73.	1.0	47
13	Etiology of hepatocellular carcinoma in Latin America: a prospective, multicenter, international study. <i>Annals of Hepatology</i> , 2010, 9, 63-69.	0.6	46
14	Breath-Ammonia Testing of Healthy Subjects and Patients with Cirrhosis. <i>Digestive Diseases and Sciences</i> , 2012, 57, 189-195.	1.1	38
15	Efficacy, tolerability and safety in the treatment of chronic hepatitis C with combination of PEG-Interferon â€“ Ribavirin in daily practice. <i>Annals of Hepatology</i> , 2010, 9, 46-51.	0.6	36
16	Latin American Association for the Study of the Liver (LAASL) Clinical Practice Guidelines: Management of Hepatocellular Carcinoma. <i>Annals of Hepatology</i> , 2014, 13, S4-S40.	0.6	34
17	Fatty liver disease, an emerging etiology of hepatocellular carcinoma in Argentina. <i>World Journal of Hepatology</i> , 2018, 10, 41-50.	0.8	34
18	Central hypothyroidism and hypophysitis during treatment of chronic hepatitis C with pegylated interferon alpha and ribavirin. <i>European Journal of Gastroenterology and Hepatology</i> , 2006, 18, 693-694.	0.8	31

#	ARTICLE	IF	CITATIONS
19	Relapse rates in chronic hepatitis B naïve patients after discontinuation of antiviral therapy with entecavir. <i>Journal of Viral Hepatitis</i> , 2014, 21, 590-596.	1.0	27
20	Acute cholestatic hepatitis after reinitiating treatment with atorvastatin. <i>Journal of Hepatology</i> , 2002, 37, 165-166.	1.8	26
21	Safety of long-term nucleos(t)ide treatment in chronic hepatitis B. <i>Expert Opinion on Drug Safety</i> , 2012, 11, 357-360.	1.0	26
22	Hepatotoxicity induced by coxibs: how concerned should we be?. <i>Expert Opinion on Drug Safety</i> , 2016, 15, 1463-1475.	1.0	26
23	Effects of immunosuppressive drugs on COVID-19 severity in patients with autoimmune hepatitis. <i>Liver International</i> , 2022, 42, 607-614.	1.9	26
24	CASE REPORT: Severe Cholestatic Hepatitis as the First Symptom of Secondary Syphilis. <i>Digestive Diseases and Sciences</i> , 2004, 49, 1401-1404.	1.1	25
25	Role of HLA-DP and HLA-DQ on the clearance of hepatitis B virus and the risk of chronic infection in a multiethnic population. <i>Liver International</i> , 2017, 37, 1476-1487.	1.9	23
26	Genetic variation in Interleukin-28B predicts SVR in hepatitis C genotype 1 Argentine patients treated with PEG IFN and ribavirin. <i>Annals of Hepatology</i> , 2011, 10, 452-457.	0.6	22
27	Effectiveness of entecavir in chronic hepatitis B NUC-naïve patients in routine clinical practice. <i>International Journal of Clinical Practice</i> , 2011, 65, 866-870.	0.8	21
28	Etiology of hepatocellular carcinoma in Latin America: a prospective, multicenter, international study. <i>Annals of Hepatology</i> , 2010, 9, 63-9.	0.6	21
29	Hepatocellular carcinoma in Latin America: Diagnosis and treatment challenges. <i>World Journal of Gastroenterology</i> , 2018, 24, 4224-4229.	1.4	19
30	Short and long term outcome of kidney transplanted patients with chronic viral hepatitis B and C. <i>Annals of Hepatology</i> , 2010, 9, 271-277.	0.6	18
31	Direct-Acting Antiviral Agents for HCV-Associated Glomerular Disease and the Current Evidence. <i>Pathogens</i> , 2019, 8, 176.	1.2	17
32	Latin American Association for the Study of the Liver (LAASL) clinical practice guidelines: management of hepatocellular carcinoma. <i>Annals of Hepatology</i> , 2014, 13 Suppl 1, S4-40.	0.6	17
33	Antiviral treatment for chronic hepatitis B in renal transplant patients. <i>World Journal of Hepatology</i> , 2014, 7, 189.	0.8	16
34	Hepatitis C Virus Infection and Outcome of Renal Transplantation. <i>Transplantation Proceedings</i> , 2007, 39, 3127-3130.	0.3	15
35	Treatment of chronic hepatitis B in clinical practice with entecavir or tenofovir. <i>World Journal of Gastroenterology</i> , 2014, 20, 7169.	1.4	15
36	Chylous ascites as the main manifestation of left ventricular dysfunction: a case report. <i>BMC Gastroenterology</i> , 2005, 5, 25.	0.8	14

#	ARTICLE	IF	CITATIONS
37	Hepatocellular Carcinoma in Renal Transplant Patients. Transplantation Proceedings, 2005, 37, 2086-2088.	0.3	14
38	Intermediate-advanced hepatocellular carcinoma in Argentina: Treatment and survival analysis. World Journal of Gastroenterology, 2019, 25, 3607-3618.	1.4	14
39	Ombitasvir/paritaprevir/ritonavir/dasabuvir±ribavirin is safe and effective in HCV-infected patients in a real-life cohort from Latin America. Journal of Medical Virology, 2017, 89, 1590-1596.	2.5	13
40	Adherence to Barcelona Clinic Liver Cancer therapeutic algorithm for hepatocellular carcinoma in the daily practice. European Journal of Gastroenterology and Hepatology, 2018, 30, 376-383.	0.8	13
41	B.A.R.C.O.S. (Brazilian Argentine Hepatitis C Collaborative Observational Study): Effectiveness and clinical outcomes of HCV treatment with daclatasvir and sofosbuvir with or without ribavirin. Journal of Viral Hepatitis, 2019, 26, 1200-1209.	1.0	13
42	The ECHO model proved to be a useful tool to increase clinicians' self-effectiveness for care of patients with Hepatitis C in Argentina. Journal of Viral Hepatitis, 2019, 26, 1284-1292.	1.0	12
43	Hepatitis B virus infection as a risk factor for chronic kidney disease. Expert Review of Clinical Pharmacology, 2019, 12, 867-874.	1.3	12
44	Entecavir treatment for chronic hepatitis B infection in end-stage renal disease and kidney transplantation. Dialysis and Transplantation, 2010, 39, 397-400.	0.2	11
45	Which Strategies Should Be Implemented in Latin America to Eradicate Hepatitis C Virus by 2030?. Clinical Liver Disease, 2019, 13, 43-45.	1.0	11
46	Argentinian clinical practice guideline for surveillance, diagnosis, staging and treatment of hepatocellular carcinoma. Annals of Hepatology, 2020, 19, 546-569.	0.6	11
47	Safety of direct-acting antivirals in the treatment of chronic hepatitis C. Expert Opinion on Drug Safety, 2014, 13, 307-319.	1.0	10
48	Hepatitis C virus genotype 1 infection: Prevalence of NS5A and NS5B resistance-associated substitutions in naïve patients from Argentina. Journal of Medical Virology, 2019, 91, 1970-1978.	2.5	10
49	Genetic variation in interleukin-28B predicts SVR in hepatitis C genotype 1 Argentine patients treated with PEG IFN and ribavirin. Annals of Hepatology, 2011, 10, 452-7.	0.6	10
50	An update on the management of hepatitis C: guidelines for protease inhibitor-based triple therapy from the Latin American Association for the Study of the Liver. Annals of Hepatology, 2013, 12, S3-S35.	0.6	9
51	Surveillance for Hepatocellular Carcinoma: Does the Place Where Ultrasound Is Performed Impact Its Effectiveness?. Digestive Diseases and Sciences, 2019, 64, 718-728.	1.1	8
52	Predictors of response to chronic hepatitis C treatment. Future Virology, 2012, 7, 1089-1101.	0.9	7
53	Polymorphisms associated with resistance to protease inhibitors in naïve patients infected with hepatitis C virus genotype 1 in Argentina: Low prevalence of Q80K. Virus Research, 2017, 240, 140-146.	1.1	7
54	Rationale for treating hepatitis C virus infection in patients with mild to moderate chronic kidney disease. Hemodialysis International, 2018, 22, S97-S103.	0.4	7

#	ARTICLE	IF	CITATIONS
55	Serious liver injury induced by Nimesulide: an international collaborative study. Archives of Toxicology, 2021, 95, 1475-1487.	1.9	7
56	An Update on Hepatocellular Carcinoma in Chronic Kidney Disease. Cancers, 2021, 13, 3617.	1.7	7
57	Clinical epidemiology of acute hepatitis C in South America. Journal of Medical Virology, 2017, 89, 276-283.	2.5	6
58	Hepatitis C Virus Diversification in Argentina: Comparative Analysis between the Large City of Buenos Aires and the Small Rural Town of O'Brien. PLoS ONE, 2013, 8, e84007.	1.1	6
59	Efficacy, tolerability and safety in the treatment of chronic hepatitis C with combination of PEG-Interferon - Ribavirin in daily practice. Annals of Hepatology, 2010, 9, 46-51.	0.6	6
60	Short and long term outcome of kidney transplanted patients with chronic viral hepatitis B and C. Annals of Hepatology, 2010, 9, 271-7.	0.6	6
61	Thioctic Acid-Induced Acute Cholestatic Hepatitis. Annals of Pharmacotherapy, 2011, 45, 1028-1028.	0.9	5
62	Does hepatitis B virus therapy reduce the risk of hepatocellular carcinoma?. Expert Opinion on Drug Safety, 2015, 14, 439-451.	1.0	5
63	Prevalence of hepatitis C virus infection according to the year of birth: identification of risk groups. European Journal of Clinical Microbiology and Infectious Diseases, 2018, 37, 247-254.	1.3	5
64	Pre-treatment prediction of response to peginterferon plus ribavirin in chronic hepatitis C genotype 3. World Journal of Hepatology, 2015, 7, 703.	0.8	5
65	Virological breakthrough and resistance in patients with chronic hepatitis B receiving nucleos(t)ide analogues in clinical practice. Hepatology, 2011, 54, 1104-1105.	3.6	4
66	Entecavir in the treatment of chronic hepatitis B in kidney transplantation. Journal of Hepatology, 2012, 56, 997-998.	1.8	4
67	Decompensated cirrhosis and liver transplantation negatively impact in DAA treatment response: Real-world experience from HCV-ALREAN cohort. Journal of Medical Virology, 2020, 92, 3545-3555.	2.5	4
68	NS3 genomic sequencing and phylogenetic analysis as alternative to a commercially available assay to reliably determine hepatitis C virus subtypes 1a and 1b. PLoS ONE, 2017, 12, e0182193.	1.1	4
69	Hepatitis C virus infection in Argentina: Burden of chronic disease. World Journal of Hepatology, 2016, 8, 649.	0.8	4
70	Effectiveness of hepatitis C treatment with pegylated interferon and ribavirin in urban minority patients. Hepatology, 2010, 51, 2231-2231.	3.6	3
71	Efficacy and safety of direct-acting antiviral agents for HCV in mild-to-moderate chronic kidney disease. Nefrologia, 2020, 40, 46-52.	0.2	3
72	Hepatitis E infection is an infrequent cause of acute hepatitis in the metropolitan area of Buenos Aires. Journal of Clinical Virology, 2020, 126, 104309.	1.6	3

#	ARTICLE	IF	CITATIONS
73	POLYMYALGIA RHEUMATICA PRESENTING AS ACUTE CHOLESTATIC HEPATITIS. Journal of Gastroenterology and Hepatology (Australia), 2005, 20, 801-802.	1.4	2
74	1177 INTERLEUKIN-28B PREDICTS SVR IN LATIN AMERICAN HEPATITIS C GENOTYPE 1 PATIENTS TREATED WITH PEG IFN AND RIBAVIRIN. Journal of Hepatology, 2011, 54, S465.	1.8	2
75	Editorial: grey zone, a new area of interest in chronic hepatitis B. Alimentary Pharmacology and Therapeutics, 2018, 47, 1547-1548.	1.9	2
76	Hepatitis C virus treatment failure: Clinical utility for testing resistance-associated substitutions. World Journal of Hepatology, 2021, 13, 1069-1078.	0.8	2
77	Seroprevalence of hepatitis B, hepatitis C and HIV infection among patients undergoing haemodialysis in Buenos Aires, Argentina. Journal of Medical Microbiology, 2021, 70, .	0.7	2
78	Hepatitis C treatment completion rates in routine clinical care. Liver International, 2010, 30, 1082-1082.	1.9	1
79	Treatment of chronic hepatitis C with pegylated interferon and ribavirin in treatment-naive patients in "true life". European Journal of Gastroenterology and Hepatology, 2011, 23, 195.	0.8	1
80	Syncope during boceprevir treatment in hepatitis C. Annals of Hepatology, 2013, 12, 837-838.	0.6	1
81	Safety and effectiveness comparing generic and original sofosbuvir-based treatment regimens in patients with hepatitis C: A prospective multicenter study from Argentina. Journal of Hepatology, 2018, 68, S280.	1.8	1
82	Efficacy and safety of direct-acting antiviral agents for HCV in mild-to-moderate chronic kidney disease. Nefrología, 2020, 40, 46-52.	0.2	1
83	Editorial: biomarkers in HBV and prediction of treatment response. Alimentary Pharmacology and Therapeutics, 2021, 53, 332-333.	1.9	1
84	1071 SHORT AND LONG TERM OUTCOME OF KIDNEY TRANSPLANTED PATIENTS WITH CHRONIC VIRAL HEPATITIS B AND C. Journal of Hepatology, 2010, 52, S414.	1.8	0
85	141 BREATH AMMONIA TESTING OF HEALTHY SUBJECTS AND PATIENTS WITH CIRRHOSIS. Journal of Hepatology, 2011, 54, S62.	1.8	0
86	Increased mortality in chronic HCV infection. Annals of Hepatology, 2012, 11, 967-968.	0.6	0
87	Incidence of de-novo hepatocellular carcinoma after treatment with direct antiviral agents for hepatitis C: A multicenter prospective cohort study from Latin America. Journal of Hepatology, 2018, 68, S546-S547.	1.8	0
88	FRI-078-Serious liver injury induced by nimesulide: An international collaboration reporting 57 cases. Journal of Hepatology, 2019, 70, e418-e419.	1.8	0
89	Direct-acting antiviral treatment failure in genotype 2 hepatitis C chronic infection. Journal of Viral Hepatitis, 2021, 28, 446-447.	1.0	0
90	Reply. Clinical Gastroenterology and Hepatology, 2021, 19, 623-624.	2.4	0

#	ARTICLE	IF	CITATIONS
91	Increased mortality in chronic HCV infection. <i>Annals of Hepatology</i> , 2012, 11, 967-8.	0.6	0
92	Simplified treatment of hepatitis C: another strategy to overcome the barriers to its elimination. <i>Medicina</i> , 2021, 81, 252-256.	0.6	0
93	TGF- $\beta$ 1 mediates cell proliferation and development of hepatocarcinogenesis by downregulating deiodinase 1 expression. <i>Medicina</i> , 2021, 81, 346-358.	0.6	0